- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06332612
Metformin Repurposing in Oral Submucous Fibrosis: Unveiling In Vitro Signaling Pathways, Progressing to Clinical Trial (MROSF)
Repurposing Metformin for the Treatment of Oral Submucous Fibrosis: Unraveling Novel Signaling Pathways In Vitro and Advancing to Clinical Trial"
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
OSF stands as a persistent inflammatory and potentially malignant condition affecting the oral cavity, marked by progressive fibrosis of the oral mucosa. The spectrum of its manifestations spans from initial inflammation to the gradual emergence of fibrous bands, leading to restricted mouth opening and mucosal rigidity. Common symptoms encompass burning sensations, difficulty in swallowing, and alterations in taste perception. This health concern has gained prominence in Pakistan, experiencing a worrisome surge in prevalence from 8.3/105 to 16.2/105 in recent years. Formerly confined to Southeast Asia, OSF has now transcended borders, manifesting in Asian immigrant communities in Britain and America, evolving into a global oral potential malignant disorder (OPMD) with a malignant rate of 9.13% .
Presently, the corticosteroid-based approach effectively reduces inflammation in OSF but falls short in addressing the underlying molecular mechanisms contributing to fibrosis. Furthermore, the prolonged use of corticosteroids raises concerns about adverse effects, including mucosal atrophy and compromised tissue integrity. This study aims to investigate the potential of metformin, a recognized emerging drug for treating fibrosis, and its anti-fibrotic properties in various organs. The established safety profile of metformin adds an advantageous aspect to its potential applications.
Numerous studies indicate that metformin exhibits anti-fibrotic effects by inhibiting TGF-β1 production, reducing phosphorylation and nuclear translocation of Smad2/3. Additionally, metformin inhibits Smad2/3 phosphorylation independently and activates AMPK, hindering Smad3 phosphorylation. The impact on reactive oxygen species (ROS) generation moderates TGF-β1-induced Smad2/3 phosphorylation and myofibroblast differentiation.Metformin has shown promise in hindering collagen production and promoting trans differentiation in various organ, including the lung, kidney, heart and adipose tissue. A clinical trial reported metformin therapy's impact on postmenopausal ovaries, patients with type 2 diabetes mellitus (T2DM) exhibited isotropic collagen organization and reduced fibrosis during oophorectomy.The observed risk reduction for ovarian cancer in T2DM women using metformin suggests its potential as an ovarian cancer prophylaxis. Despite conflicting clinical trial results in liver fibrosis, metformin consistently improves hepatocyte damage and inflammation. Clinical trials have explored the role of metformin antitumor activity when combined with conventional chemotherapeutic drugs and in idiopathic pulmonary fibrosis it inhibits TGFβ1, suppressing collagen formation, activating PPARγ signaling and inducing lipogenic differentiation.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
- Name: Afifa Razi, FCPS
- Phone Number: +92 300 2247389
- Email: afifa.razi@zu.edu.pk
Study Contact Backup
- Name: Shumaila Usman, PhD
- Phone Number: +92 336 1882779
- Email: shumaila.usman@zu.edu.pk
Study Locations
-
-
Sindh
-
Karachi, Sindh, Pakistan, 74700
- Ziauddin University
-
Contact:
- Shumaila Usman, PhD
- Phone Number: +92 336 1882779
- Email: shumaila.usman@zu.edu.pk
-
Contact:
- Afifa Razi, FCPS OMFS
- Phone Number: +92 300 2247389
- Email: afifa.razi@zu.edu.pk
-
Principal Investigator:
- Afifa Razi, FCPS
-
Sub-Investigator:
- Shumaila Usman, PhD
-
Sub-Investigator:
- Yamna Khurshid, PhD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Patients with OSF- palpable bands on oral examination
- Patients with limited mouth opening due to OSF
- Patients who have not received any treatment for OSF in the previous three months
- Patients with habits of pan, Chalia, Ghutka
- Age group between 18 and 45 years
Exclusion Criteria:
- Patients presenting with both OSCC and OSF
- Patients with limited mouth opening due to impaction of the third molar (impaction of third molar results in limited mouth opening hence such patients are excluded since limited mouth opening due to third molar impaction can be mistaken for OSF).
- Patients with limited mouth opening due to temporomandibular joint disorder (temporomandibular joint disorders can limit the ability of patient to open their mouth and hence can be mistaken for OSF)
- Any history of Metformin intolerance or contraindications.
- Presence of other severe medical conditions along with drug therapy.
- Pregnancy or lactation.
- Participation in other clinical trials concurrently.
- Inability to provide informed consent.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Standard
Group 1: Standard treatment with topical cream betamethasone and Pentoxifylline tablet.
|
Group 1will recieve topical cream betamethasone thrice daily
Other Names:
Group 1 will receive Pentoxifylline tablet 400 mg twice daily
Other Names:
|
Experimental: MetforminO
Metformin 500 mg thrice daily.
|
Group B will receive Metformin 500 mg thrice daily.
Group C will receive topical cream metformin thrice daily.
Other Names:
|
Experimental: MetforminT
Topical cream metformin thrice daily
|
Group B will receive Metformin 500 mg thrice daily.
Group C will receive topical cream metformin thrice daily.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cell Viability
Time Frame: 8 months
|
Cell Viability by MTT Assay Unit: Percentage Assessment of cell viability will be reported as a percentage of untreated control cells.
|
8 months
|
Cytotoxicity
Time Frame: 8 Months
|
Cytotoxicity Unit: Percentage Measurement of cytotoxicity will be presented as a percentage relative to untreated control cells.
|
8 Months
|
Morphological Changes Cell Shape
Time Frame: 8months
|
Unit: Qualitative description Cell shape alterations will be described qualitatively based on microscopic observations.
|
8months
|
Morphological Change Cell Density
Time Frame: 8 months
|
Unit: Cells per unit area Changes in cell density will be quantified and reported as cells per unit area.
Sub-Measure 3: Extracellular Matrix (ECM) Structure Unit: Qualitative description Alterations in ECM structure will be qualitatively assessed.
|
8 months
|
Morphological Change Extracellular Matrix (ECM) Structure
Time Frame: 8 months
|
Extracellular Matrix (ECM) Structure Unit: Qualitative description Alterations in ECM structure will be qualitatively assessed.
|
8 months
|
Cell Migration Assays
Time Frame: 8months
|
Unit: Distance migrated (micrometers) The extent of cell migration will be quantified as the distance migrated from the original point.
|
8months
|
Cell Invasion Assays
Time Frame: 8 months
|
Unit: Invaded area (e.g., square millimeters) Assessment of cell invasion will be presented as the invaded area relative to untreated control cells.
|
8 months
|
Apoptosis Analysis
Time Frame: 8months
|
Unit: Percentage Apoptotic cells will be quantified and reported as a percentage of the total cell population.
|
8months
|
Assess Signaling pathway with optimal metformin concentration
Time Frame: 9 months
|
To evaluate the effect of TGF-beta Smad 2/3 and wnt/b-catenin signaling pathways in vitro
|
9 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clinical Oral Mucosal Characteristics
Time Frame: 9 months
|
Unit: Descriptive score (based on a scale ranging from 0 to 3 (normal to severe).0=No
changes 1=Soreness 2=Soreness and ulceration 3=Soreness, ulceration and ability to use a liquid diet only
|
9 months
|
Patient Burning sensation pain
Time Frame: 9 months
|
Unit: Units on a scale (Verbal numeric rating scale graded on a 10-point scale from 0 to 10, where 0 indicated no burning sensation while 10 represented the worst burning sensation)
|
9 months
|
Patient Mouth Opening
Time Frame: 9 months
|
Unit: Millimeters on a scale of Grade 0 = > 35 mm, Grade1= 26-35mm, Grade 2= 15-25mm, Grade 3: < 10mm
|
9 months
|
Collaborators and Investigators
Sponsor
Publications and helpful links
General Publications
- Yang SF, Wang YH, Su NY, Yu HC, Wei CY, Yu CH, Chang YC. Changes in prevalence of precancerous oral submucous fibrosis from 1996 to 2013 in Taiwan: A nationwide population-based retrospective study. J Formos Med Assoc. 2018 Feb;117(2):147-152. doi: 10.1016/j.jfma.2017.01.012. Epub 2017 Apr 5.
- Shen YW, Shih YH, Fuh LJ, Shieh TM. Oral Submucous Fibrosis: A Review on Biomarkers, Pathogenic Mechanisms, and Treatments. Int J Mol Sci. 2020 Sep 30;21(19):7231. doi: 10.3390/ijms21197231.
- Septembre-Malaterre A, Boina C, Douanier A, Gasque P. Deciphering the Antifibrotic Property of Metformin. Cells. 2022 Dec 16;11(24):4090. doi: 10.3390/cells11244090.
- Wu M, Xu H, Liu J, Tan X, Wan S, Guo M, Long Y, Xu Y. Metformin and Fibrosis: A Review of Existing Evidence and Mechanisms. J Diabetes Res. 2021 Apr 29;2021:6673525. doi: 10.1155/2021/6673525. eCollection 2021.
- Teague TT, Payne SR, Kelly BT, Dempsey TM, McCoy RG, Sangaralingham LR, Limper AH. Evaluation for clinical benefit of metformin in patients with idiopathic pulmonary fibrosis and type 2 diabetes mellitus: a national claims-based cohort analysis. Respir Res. 2022 Apr 11;23(1):91. doi: 10.1186/s12931-022-02001-0.
- Pimentel I, Lohmann AE, Ennis M, Dowling RJO, Cescon D, Elser C, Potvin KR, Haq R, Hamm C, Chang MC, Stambolic V, Goodwin PJ. A phase II randomized clinical trial of the effect of metformin versus placebo on progression-free survival in women with metastatic breast cancer receiving standard chemotherapy. Breast. 2019 Dec;48:17-23. doi: 10.1016/j.breast.2019.08.003. Epub 2019 Aug 22.
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Pathologic Processes
- Stomatognathic Diseases
- Mouth Diseases
- Fibrosis
- Oral Submucous Fibrosis
- Hypoglycemic Agents
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Vasodilator Agents
- Enzyme Inhibitors
- Anti-Inflammatory Agents
- Platelet Aggregation Inhibitors
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Protective Agents
- Anti-Asthmatic Agents
- Respiratory System Agents
- Antioxidants
- Phosphodiesterase Inhibitors
- Free Radical Scavengers
- Radiation-Protective Agents
- Betamethasone
- Betamethasone Valerate
- Betamethasone-17,21-dipropionate
- Betamethasone benzoate
- Betamethasone sodium phosphate
- Metformin
- Pentoxifylline
Other Study ID Numbers
- 8420224AROM
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Oral Submucous Fibrosis
-
The Oxford Dental College, Hospital and Research...CompletedOral SubMucous Fibrosis
-
Altamash Institute of Dental MedicineCompletedTumor | Pentoxifylline | Triamcinolone | Vitamin E | Oral Submucosa FibrosisPakistan
-
H.K.E.S's S.Nijalingappa Institute of Dental Science...Unknown
-
Panineeya Mahavidyalaya Institute of Dental Sciences...Completed
-
Ziauddin UniversityCompletedOral Submucous FibrosisPakistan
-
The Oxford Dental College, Hospital and Research...Credora Life Sciences, IndiaCompletedOral Submucous Fibrosis
-
Government College of Dentistry, IndoreCompletedOral Submucous Fibrosis
-
SVS Institute of Dental SciencesUnknownOral Submucous FibrosisIndia
-
Sir Ganga Ram HospitalRecruiting
-
The University of Hong KongNot yet recruitingOral Cancer | Oral Leukoplakia | Erosive Lichen Planus | Oral Submucous Fibrosis | Proliferative Verrucous Leukoplakia | Oral Erythroplakia
Clinical Trials on betamethasone dipropionate
-
Primus PharmaceuticalsProsoft ClinicalCompletedPlaque PsoriasisUnited States
-
Wake Forest University Health SciencesDermavant Sciences, Inc.Not yet recruitingICD10 Code L40.9 for PsoriasisUnited States
-
Padagis LLCCompleted
-
Garlapati KomaliUnknown
-
Derm Research, PLLCCompletedPlaque PsoriasisUnited States
-
LEO PharmaCompleted
-
HaEmek Medical Center, IsraelWithdrawnComparison of 2 Doses of Corticosteroid Subacromial Injections for the Treatment of Painful ShoulderBursitis | TendonitisIsrael
-
Jooheung LeeCompletedPsoriasis VulgarisKorea, Republic of
-
LEO PharmaCompleted